1 / 26

Corporate Presentation

Corporate Presentation. September 2010. 2776 University Drive Coral Springs, FL USA Phone: (954) 509-0911 Fax: (877) 895-5647 investor.relations@NutraPharma.com www.NutraPharma.com. SAFE HARBOR. Nutra Pharma Corporation.

cianna
Télécharger la présentation

Corporate Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Corporate Presentation September 2010 2776 University DriveCoral Springs, FL USA Phone: (954) 509-0911 Fax: (877) 895-5647 investor.relations@NutraPharma.com www.NutraPharma.com

  2. SAFE HARBOR Nutra Pharma Corporation Statements made in the course of this presentation that state the Company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future are forward-looking statements. It is important to note that the Company’s actual results could differ materially from those projected in such forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company’s SEC filings, including but not limited to the Company’s report on Form 10-K for the year ended December 31, 2009; the Company’s report on Form 10-Q for the quarter ended June 30, 2010. Copies of these filings may be obtained by contacting the Company or the SEC.

  3. Overview Nutra Pharma is a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases.

  4. INTRODUCTION Nutra Pharma Overview Nutra Pharma, through its subsidiaries, carries out basic drug discovery research and clinical development. The Company also manufactures, through its subsidiary over-the-counter (OTC) drug products for the treatment of moderate to severe chronic pain. These pain relievers are sold under the brands Cobroxin and Nyloxin. Drug Development In addition to manufacturing Cobroxin and Nyloxin, ReceptoPharm is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Outside of its role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. Medical Devices Designer Diagnostics is the wholly-owned medical devices subsidiary of Nutra Pharma. The Company was established in 2005 for the marketing and sales of rapid diagnostics test kits for infectious diseases, including Nontuberculous Mycobacteria (NTM) and Tuberculosis (TB).

  5. MANAGEMENT TEAM Nutra Pharma Overview

  6. BOARD OF DIRECTORS Nutra Pharma Overview

  7. Marketed Pain Relievers Nutra Pharma manufactures and markets over-the-counter (OTC) drug products for the treatment of moderate to severe chronic pain. These products are sold under the Cobroxin and Nyloxin brands.

  8. COBROXIN OVERVIEW Pain Products • Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. • Cobroxin was launched in August 2009 and is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. • Additional Benefits to Cobroxin Include: • All Natural • Non-Addictive • Non-Narcotic • Non-Opiate • Long Lasting

  9. COBROXIN OVERVIEW Pain Products Cobroxin is currently sold at the following retailers:

  10. NYLOXIN OVERVIEW Pain Products Nyloxin is available in both everyday strength and extra strength. Nyloxin is available an over-the-counter (OTC) pain reliever clinically proven to treat Stage 2 (moderate to severe) and Stage 3 (severe) chronic pain. Nyloxin was launched in mid-2010 as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, and as topical gel for treating joint pain, arthritis pain and pain from repetitive stress.

  11. MARKET POTENTIAL Pain Products • Pain is the single most common reason patients seek medical care and accounts for half of all physician office visits in the United States. • According to the American Pain Foundation, each year, more than 25 million people in the United States experience acute pain as a result of injury or surgery. Additionally, more than 50 million people in the United States are affected by ongoing chronic pain. • Both Cobroxin and Nyloxin: • Make potent pain relief accessible to: • People without healthcare insurance (42 million) • People without prescription coverage • People afraid of opiate side effects • People subject to drug screening for work • People for whom OTC NSAIDs didn’t work and are just living with the pain • Doctors afraid to prescribe opiates • Target consumers not well-served by current products

  12. Drug Discovery Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, conducts research into a number of products with applications for neurological, immunological, autoimmune and viral conditions.

  13. DRUG DISCOVERY OVERVIEW Drug Discovery Nutra Pharma’s wholly-owned subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products for the billion-dollar biologics market. The Company has two leading drug candidates: RPI-MN and RPI-78M. RPI-MN RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and Human Immunodeficiency Virus (HIV). It is being developed first for the treatment of HIV. RPI-78MRPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS). RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to ReceptoPharm, the drugs are created through a process of chemical modification.

  14. BENEFITS OF RPI-MN AND RPI-78M Drug Discovery RPI-MN and RPI-78M possess several desirable properties as drugs: They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose. They display no serious adverse side effects following years of investigations in humans and animals. They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug. They are easy to administer. RPI-78M can be administered orally -- a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.

  15. SPECIFIC BENEFITS OF RPI-MN Drug Discovery Benefits of Nutra Pharma’s HIV/AIDs Treatment

  16. SPECIFIC BENEFITS OF RPI-78M Drug Discovery Benefits of Nutra Pharma’s Multiple Sclerosis (MS) Treatment

  17. RESEARCH & DEVELOPMENT PIPELINE Drug Discovery ReceptoPharm's research and development pipeline consists of several novel therapies in various stages of development to prevent and/or treat Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN), Herpes, Rheumatoid Arthritis (RA) and Pain.

  18. PUBLISHED RESEARCH Drug Discovery Cobratoxin Inhibits Pain-Evoked Discharge of Neurons in Thalamic Parafascicular Nucleus in Rats: Involvement of cholinergic and serotonergic systems // Toxicon (April 2009) Alpha Cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application // Critical Reviews™ in Immunology (Volume 27 / Issue 4 2007) Analgesic Effects of Receptin, a Chemically Modified Cobratoxin from Thailand Cobra Venom// Neuroscience Bulletin (September 2006) Amelioration of Acute and Relapsing Stages of the Experimental Allergic Encephalomyelitis by Cobra Toxins// Biomedical Sciences Instrumentation (June 2006) A Long-Form a-Neurotoxin from Cobra Venom Produces Potent Opioid-Independent Analgesia// ActaPharmacologicaSinica(April 2006) A Short-Chain a-Neurotoxin from Najanajaatra Produces Potent Cholinergic-Dependent Analgesia// Neuroscience Bulletin (March 2006)

  19. Contract Research Services ReceptoPharm has installed the pathways to develop, produce and supply clinical material for Phase I and II studies at the highest levels. In 2008, the Company began offering services catering to small and start-up biotechnology companies.

  20. PARTNERING WITH RECEPTOPHARM Contract Research Services As a clinical stage company specializing in biologics, ReceptoPharm has cleared many of the hurdles that face emerging biotech companies. Below are the top reasons that companies choose to partner with ReceptoPharm as its CRO: Therapeutic experience encompassing infectious disease, autoimmune conditions, neurological disorders and oncology indications. A renowned team of scientists, led by Dr. Paul Reid, specializing in human and veterinary regulatory affairs for the United States, Canada, and Europe, and drug applications (pre IND, IND and Orphan), drug production, new drug development, clinical trial design, patient monitoring, and experimental design. Significant investment in establishing a production facility to meet US and EU standards, including the installation of quality systems to meet GMP standards and ISO Class 5 certification.

  21. A GLOBAL VIEW ON DRUG DEVELOPMENT Contract Research Services ReceptoPharm prides itself on taking a global view on drug development; whether it’s preparing submissions, protocols, formulations, or organizing clinical trials internationally. ReceptoPharm has invested heavily in establishing its own production facility to meet US and EU standards, including the installation of quality systems to meet GMP standards. Its commitment to maintaining the highest quality standards can now be used as a resource by other biopharmaceutical companies.

  22. TOP-RATED DRUG PRODUCTION FACILITIES Contract Research Services Establishing and maintaining a qualified drug production facility can represent a significant drain on a small company’s resources. ReceptoPharm understands that its investment in manufacturing and its first-hand knowledge in drug discovery and development can be very valuable assets to small companies that do not have these resources or capabilities in-house. Working with ReceptoPharm, through its ISO class 5 and GMP certified facilities, will allow these companies to avoid considerable clinical development expenses and allow them to focus on a more important task, expeditiously getting their products to the next stage.

  23. PRE-PRODUCTION STUDIES CONTRACT MANUFACTURING SERVICES US & EU REGULATORY SUPPORT QUALITY SYSTEMS/GMP CERTIFICATION STERILE FILLING CAPABILITIES Contract Research Services • Drug Formulation • ISO 5 Sterile Filling Suite, Single and Multi-Dose Liquids for Injection • Clinical Trial Supplies to FDA & EU Requirements • Packaging and Shipment to Sites • Release Testing and Certification • Stability Studies • Formulation • Adventitious Viral Testing • Preservative Efficacy Testing • Assay Development/Potency Testing • Methods Development • FDA Drug Applications, IND Preparation • EU Submissions, IMPD Preparation • Installation of Quality Systems Using Our SOPs • GMP Audits • GMP Training • QA Function • IQ/OQ/PQ • Validations (Equipment and Processes) ReceptoPharm can manually fill a variety of drug products for your clinical development projects in the US and EU. While ReceptoPharm specializes in biologics, including mAbs, natural, recombinant and synthetic proteins, it can also prepare and fill pharmaceutical products in its ISO class 5 cleanroom facilities.

  24. Medical devices Nutra Pharma’s wholly-owned drug discovery subsidiary, Designer Diagnostics, is a biotechnology sales and marketing company founded for the sale of diagnostics test kits for infectious diseases.

  25. LEADING TEST KIT TECHNOLOGY Test Kit Technology Designer Diagnostics Test Kits provide a highly cost effective, highly efficient, low infrastructure solution for identifying and testing sensitivity of Nontuberculous Mycobacteria (NTM) that are capable of utilizing paraffin wax as a sole carbon source or those that are hydrophobic. Additionally Designer Diagnostics provides an efficient solution for the rapid identification and sensitivity testing of Tuberculosis (TB).

  26. Contact Nutra Pharma 2776 University DriveCoral Springs, FL 33065 Phone: (954) 509-0911 Fax: (877) 895-5647 investor.relations@NutraPharma.com www.NutraPharma.com

More Related